13F-HR filed by Foresite Capital Management IV, LLC
Foresite Capital Management IV, LLC filed this 13F-HR for the quarter ended 2023-06-30, filed 2023-08-11, with 7 holding rows worth $203,401,092.
- Accession
- 0001104659-23-090055
- Filer
- CIK 1704132
- Filed
- 2023-08-11
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2023
A holdings report, 7 entries on the cover page, a total value of $203,401,092 stated on the cover page (in dollars after the unit check, H1), rows summing to $203,401,092 with VALUE read as dollars as filed, 13F file number 028-18415. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| PHARVARIS NV | N69605108 | COMMON STOCK | 3,743,450 | $56,675,833 | dollars as filed | |
| LYELL IMMUNOPHARMA INC | 55083R104 | COM | 9,700,000 | $30,846,000 | dollars as filed | |
| KINNATE BIOPHARMA INC | 49705R105 | COM | 9,671,643 | $29,305,078 | dollars as filed | |
| ACLARIS THERAPEUTICS INC COM | 00461U105 | Stock | 2,808,034 | $29,119,313 | dollars as filed | |
| KURA ONCOLOGY INC COM | 50127T109 | Stock | 1,849,947 | $19,572,439 | dollars as filed | |
| CYMABAY THERAPEUTICS INC | 23257D103 | COM | 1,787,094 | $19,568,679 | dollars as filed | |
| SYNDAX PHARMACEUTICALS INC | 87164F105 | COM | 875,000 | $18,313,750 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-23-090055 | this filing | 2023-08-11 | acceptance time not in the bulk data set |